FRES Overview

AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.

Wall Street analysts forecast FRES stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FRES is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fresh2 Group Ltd revenue for the last quarter amounts to 4.34M USD, increased 33.84

Fresh2 Group Ltd. EPS for the last quarter amounts to -0.27 USD, decreased -98.79

Fresh2 Group Ltd (FRES) has 75 emplpoyees as of May 12 2026.

Today FRES has the market capitalization of 8.12M USD.